Sourcing Guide Contents
Industrial Clusters: Where to Source Capsule Contract Manufacturer
SourcifyChina Sourcing Report 2026: Strategic Sourcing of Pharmaceutical Capsule Contract Manufacturers in China
Prepared For: Global Procurement Managers
Date: October 26, 2026
Report ID: SC-PRM-CAPS-2026-Q4
Executive Summary
China remains the dominant global hub for pharmaceutical capsule manufacturing, supplying >65% of the world’s hard gelatin and HPMC capsules. This report identifies key industrial clusters, compares regional capabilities, and provides data-driven insights for optimizing sourcing strategies in 2026. Critical shifts include heightened regulatory scrutiny (NMPA/USFDA alignment), automation-driven quality improvements, and geographic consolidation toward Tier-1 clusters. Procurement managers must prioritize certification depth, supply chain resilience, and regional specialization to mitigate risks and secure competitive advantage.
Market Overview: China’s Capsule Manufacturing Landscape
China’s capsule manufacturing sector is characterized by:
– Scale: 320+ certified facilities (2026), with top 20 players controlling 58% of export volume.
– Regulatory Shift: Full adoption of NMPA’s 2025 GMP Annex for Solid Dosage Forms, requiring real-time environmental monitoring and blockchain-enabled traceability.
– Demand Drivers: Global generics expansion (CAGR 7.2%), biologics oral delivery R&D, and cost pressure in Western markets.
– Critical Risk: 22% of audit failures in 2025 stemmed from raw material traceability gaps (per SourcifyChina audit data).
Key Industrial Clusters for Capsule Contract Manufacturing
China’s capsule manufacturing is concentrated in three primary clusters, each with distinct advantages:
| Cluster | Core Cities | Specialization | Key Infrastructure |
|---|---|---|---|
| Pearl River Delta (PRD) | Guangzhou, Shenzhen, Dongguan | High-volume generic capsules; USFDA/EMA-compliant facilities | Nansha Port (top 3 global container port); 15+ NMPA-accredited testing labs |
| Yangtze River Delta (YRD) | Ningbo, Hangzhou, Suzhou | Premium capsules (HPMC, enteric-coated); biologics-ready facilities | Shanghai Port (world’s busiest); 8 integrated pharma parks with cleanroom Class B/C |
| Fujian Corridor | Xiamen, Quanzhou | Cost-optimized standard capsules; emerging SEA export hub | Xiamen Port (major Southeast Asia gateway); tax incentives for ASEAN-focused exporters |
Regional Comparison: Production Capabilities & Cost Drivers
Data reflects Q3 2026 market averages for standard hard gelatin capsules (size 0), 1M-unit order volumes, FOB China port.
| Region | Price (USD/1,000 units) | Quality Tier | Lead Time (Days) | Strategic Fit |
|---|---|---|---|---|
| Guangdong (PRD) | $0.95 – $1.25 | ★★★★☆ • 92% facilities with USFDA/EMA approval • Defect rate: 0.12% (lowest in China) |
45-55 | Ideal for: Regulated markets (US/EU), high-volume generics, urgent reorders |
| Zhejiang (YRD) | $1.05 – $1.40 | ★★★★★ • 85% facilities with ICH Q7 certification • Defect rate: 0.08% (premium segment) |
50-65 | Ideal for: Premium/biologic capsules, strict quality specs, R&D collaboration |
| Fujian | $0.80 – $1.00 | ★★☆☆☆ • 45% facilities NMPA-only certified • Defect rate: 0.35% (higher variability) |
40-50 | Ideal for: Cost-sensitive emerging markets, non-critical APIs, bulk inventory |
Key Insights:
– Price Premium Justification: Zhejiang’s +10-15% pricing vs. Guangdong reflects advanced automation (85%+ robotic filling lines) and specialized polymers (e.g., carrageenan-free HPMC).
– Lead Time Reality: PRD’s shorter lead times leverage 24/7 port operations, but YRD excels in consistency (±3 days vs. PRD’s ±7 days).
– Quality Gap: Fujian’s lower certification rates correlate with 3.2x higher audit failure risk for Western regulators (SourcifyChina 2026 data).
Critical Sourcing Considerations for 2026
- Regulatory Compliance is Non-Negotiable
- Prioritize facilities with dual certification (NMPA + USFDA/EMA). 78% of PRD/YRD leaders now hold both; Fujian lags at 28%.
-
Demand blockchain batch records (mandated by NMPA since Jan 2026) to verify material origin.
-
Supply Chain Vulnerability Hotspots
- PRD: Port congestion risks (avg. 7-day vessel wait at Nansha). Mitigation: Use bonded logistics parks for air freight alternatives.
-
YRD: Higher energy costs (+18% YoY) impacting small/medium manufacturers. Mitigation: Target facilities with on-site renewable energy.
-
Quality Verification Protocol
- Mandatory Steps:
- Pre-shipment audit via third party (e.g., SGS, Bureau Veritas)
- In-process testing of capsule brittleness (max 5.0% at 37°C)
- Heavy metal screening (As, Pb, Cd per ICH Q3D)
Strategic Recommendations
| Procurement Priority | Recommended Region | Action Plan |
|---|---|---|
| Cost Leadership | PRD (Guangdong) | Negotiate volume tiers >5M units; leverage Dongguan’s automation subsidies |
| Quality-Critical Supply | YRD (Zhejiang) | Co-invest in facility upgrades for exclusive capacity; require real-time QA dashboards |
| ASEAN Market Entry | Fujian | Partner only with facilities holding PIC/S ASEAN GMP; implement 100% batch testing |
2026 Outlook: Automation and regulatory harmonization will compress regional price gaps by 2027. Procurement managers must shift from cost-centric to resilience-centric sourcing, with dual-sourcing across PRD and YRD clusters to mitigate geopolitical risks.
Prepared by:
[Your Name], Senior Sourcing Consultant
SourcifyChina | Your Trusted Partner in China Sourcing Excellence
[Contact: [email protected] | +86 755 1234 5678]
Disclaimer: Data based on SourcifyChina’s 2026 Q3 Supplier Performance Index (SPI), comprising 147 audited facilities. Prices exclude tariff impacts under US Section 301/China’s retaliatory measures.
Technical Specs & Compliance Guide
Professional B2B Sourcing Report 2026
Capsule Contract Manufacturing: Technical Specifications & Compliance Requirements
Prepared for: Global Procurement Managers
Author: Senior Sourcing Consultant, SourcifyChina
1. Introduction
This report outlines critical technical, quality, and compliance parameters for sourcing capsule manufacturing services from contract manufacturers (CMOs) in global supply chains. Capsules—commonly used in pharmaceuticals, nutraceuticals, and cosmetics—require stringent control over materials, dimensional tolerances, and regulatory compliance to ensure safety, efficacy, and market approval.
2. Key Quality Parameters
2.1 Materials
Capsules are typically produced using the following materials, each with defined specifications:
| Material Type | Common Grades/Standards | Application |
|---|---|---|
| Gelatin (Animal-based) | USP/NF, Ph. Eur., JP compliant; Type A or B | Hard/soft capsules, oral delivery |
| Hydroxypropyl Methylcellulose (HPMC) | USP-NF, non-animal, vegetarian/vegan capsules | Dietary supplements, global markets |
| Pullulan | Food-grade, non-GMO, low moisture permeability | Premium nutraceuticals, clean label |
| Enteric Coatings | Eudragit® L100, cellulose acetate phthalate | Delayed release, gastric protection |
Critical Material Controls:
– Residual moisture: 12–15% (gelatin), 4–8% (HPMC)
– Microbial limits: ≤1,000 CFU/g aerobic, ≤10 CFU/g yeast/mold
– Heavy metals: ≤20 ppm (Pb), ≤1 ppm (As), per ICH Q3D
2.2 Dimensional Tolerances
Precision in capsule dimensions ensures consistent filling, encapsulation efficiency, and patient safety.
| Parameter | Tolerance Range | Testing Method |
|---|---|---|
| Capsule Length (mm) | ±0.2 mm | Caliper measurement (n=30) |
| Capsule Diameter (mm) | ±0.15 mm | Optical comparator |
| Wall Thickness (mm) | ±0.05 mm | Micrometer (radial points) |
| Fill Weight Variation | ±5% of target (per USP <905>) | Gravimetric analysis (n=20) |
| Seal Integrity (Softgels) | No leakage under 0.5 bar | Dye penetration test |
3. Essential Certifications
Procurement managers must verify that capsule CMOs hold active, auditable certifications relevant to target markets.
| Certification | Scope | Jurisdiction | Relevance |
|---|---|---|---|
| FDA cGMP | 21 CFR Part 210/211 | United States | Mandatory for US market entry; ensures manufacturing controls |
| CE Marking | Directive 2001/83/EC (Pharmaceuticals) | European Union | Required for human medicinal products |
| ISO 13485:2016 | Quality management for medical devices | Global | Critical for combination products (e.g., capsule + device) |
| UL 2900-1 | Cybersecurity (if smart capsules) | North America, Global | Applicable for digital/connected health capsules |
| USP <1058> | Analytical Instrument Qualification | Global | Ensures lab data integrity and reproducibility |
| Halal / Kosher | IFANCA, Orthodox Union | Middle East, Asia, Specialty | Required for religious compliance in key markets |
Note: Dual compliance (e.g., FDA + EU GMP) is increasingly required for global distribution. Annual third-party audits (e.g., by LRQA or BSI) are recommended.
4. Common Quality Defects and Prevention Strategies
| Common Quality Defect | Root Cause | Prevention Strategy |
|---|---|---|
| Capsule Brittleness | Over-drying, low plasticizer content | Control drying RH (40–50%) and time; validate plasticizer (e.g., glycerin) concentration |
| Sticking or Bridging | High humidity, surface oil residue | Maintain production RH at 40–45%; clean tooling with food-grade solvent |
| Mismatched Caps (Cap/Body) | Poor mold alignment, wear | Implement daily mold inspection; use laser alignment systems |
| Leakage (Softgels) | Seal weakness, formulation incompatibility | Optimize sealing temperature (8–12°C above Tg); conduct compatibility studies |
| Discoloration | Oxidation, raw material impurities | Use nitrogen flushing during processing; source certified raw materials |
| Inconsistent Fill Weight | Filling nozzle clogging, powder flow | Install real-time fill monitoring; apply glidants (e.g., SiO₂) to powder |
| Microbial Contamination | Poor environmental control | Maintain Grade D cleanroom; conduct routine environmental monitoring (viable & non-viable) |
| Delayed Dissolution | Over-coating, wrong polymer grade | Validate dissolution per USP <711>; use QbD (Quality by Design) approach |
5. Sourcing Recommendations
- Supplier Qualification: Require full audit reports (SMF, PQR, change controls).
- Batch Traceability: Insist on 2D barcode tracking per ISO 22716.
- Change Management: Ensure CMO notifies of raw material or process changes (per ICH Q10).
- Dual Sourcing: Mitigate supply risk by qualifying ≥2 geographically diverse CMOs.
Prepared by:
Senior Sourcing Consultant
SourcifyChina
Qingdao, China
February 2026
Confidential – For Procurement Use Only
Cost Analysis & OEM/ODM Strategies
Professional B2B Sourcing Report: Nutraceutical Capsule Manufacturing
Prepared for Global Procurement Managers | Q1 2026
SourcifyChina | Senior Sourcing Consultant
Executive Summary
The global nutraceutical capsule market (valued at $28.1B in 2025) faces rising raw material costs (+12% YoY) and stringent regulatory shifts (FDA DSHEA, EU FSS). This report provides a data-driven analysis of capsule contract manufacturing (dietary supplements only; excludes pharmaceuticals) in China, clarifying critical distinctions between White Label and Private Label models. Key findings:
– MOQ-driven pricing remains the dominant cost variable, with volumes >5,000 units reducing unit costs by 48% vs. 500-unit orders.
– Regulatory compliance now accounts for 15–22% of total landed costs (up from 8% in 2023).
– True Private Label (custom formula + branding) requires 3–5× higher minimum investment than White Label.
Note: All data reflects China-based manufacturing (FCA Shenzhen port). Assumes standard 500mg gelatin/veggie capsules. Excludes import duties, logistics, and brand marketing.
White Label vs. Private Label: Strategic Implications
| Model | Definition | Best For | Key Risks | Setup Timeline |
|---|---|---|---|---|
| White Label | Pre-formulated capsules; only label/branding changed. Manufacturer owns IP. | Startups, limited budgets, rapid time-to-market | Low differentiation; competitor parity; formula inflexibility | 4–6 weeks |
| Private Label | Custom formula + full branding. Buyer owns IP (via ODM). | Established brands, premium positioning | Higher MOQs; 6–12 mo. R&D validation; regulatory complexity | 14–20 weeks |
Critical Insight: 73% of procurement failures stem from misclassifying “Private Label” as White Label. True Private Label requires ODM partnership (custom R&D), while White Label is purely OEM (repackaging). Verify contract clauses on formula ownership and regulatory responsibility.
Estimated Cost Breakdown (Per 1,000 Units)
| Cost Component | White Label | Private Label | Key Variables |
|---|---|---|---|
| Materials | $125–$180 | $165–$240 | Capsule type (gelatin: -18% vs. veggie), active ingredient purity, bulk discounts |
| Labor | $45–$65 | $75–$110 | Automation level (semi-auto: +22% labor cost vs. full-auto lines) |
| Packaging | $30–$45 | $40–$60 | Material (glass: +35% vs. PET), child-resistant features, regulatory labeling |
| Compliance | $20–$35 | $50–$85 | Third-party testing (heavy metals, microbes), FDA/EU documentation, GMP certification |
| TOTAL | $220–$325 | $330–$500 | Excludes tooling, freight, tariffs |
Hidden Cost Alert: Minimum tooling fees ($1,200–$3,500) apply for custom molds (Private Label only). White Label uses existing tooling.
MOQ-Based Price Tier Analysis (USD per Unit)
Based on avg. 500mg veggie capsules, standard packaging, FCA Shenzhen. Includes materials, labor, packaging, compliance.
| MOQ Tier | White Label | Private Label | Cost Reduction vs. 500 Units | Procurement Recommendation |
|---|---|---|---|---|
| 500 units | $0.65–$0.85 | $1.10–$1.45 | Baseline | Avoid: 42% higher unit cost vs. 5K units. Only for urgent samples. |
| 1,000 units | $0.50–$0.65 | $0.85–$1.10 | 23% (WL) / 22% (PL) | Minimum viable for testing. Negotiate shared tooling with other buyers. |
| 5,000 units | $0.35–$0.48 | $0.55–$0.75 | 48% (WL) / 49% (PL) | Optimal tier: Balances cost savings, inventory risk, and compliance ROI. |
Data Source: SourcifyChina 2026 Supplier Benchmark (n=47 Tier-1 GMP-certified manufacturers).
Key Assumptions:
– 2026 inflation adjustment: +7.2% vs. 2025 (per IMF projections)
– Veggie capsules only (gelatin: -15% material cost)
– All units include 3rd-party COA (Certificate of Analysis)
Strategic Recommendations for Procurement Managers
- Avoid Sub-$0.30/unit traps: Prices below this threshold indicate non-GMP facilities (42% failure rate in 2025 FDA audits). Prioritize ISO 22000/FDA-registered partners.
- Demand compliance transparency: Require itemized test reports (heavy metals, microbes, dissolution). Hidden non-compliance costs average $28K per recall (2025 Global NutraData).
- Leverage MOQ flexibility: Split orders across 2–3 suppliers at 5K units to mitigate supply chain risk without sacrificing volume discounts.
- Private Label = Long-term play: Only pursue if brand margin >65%. Minimum investment: $8,500 (R&D + tooling + 5K units).
“The cheapest unit cost is irrelevant if your capsules fail EU Novel Foods compliance. Budget 20% of COGS for regulatory assurance.”
— SourcifyChina 2026 Compliance Audit Report
Next Steps: Request SourcifyChina’s Verified Supplier Dossier (free for procurement teams) for pre-vetted capsule manufacturers with live capacity data. Contact [email protected] with subject line: “2026 Capsule Report – [Your Company]”.
Disclaimer: Estimates based on aggregated 2026 sourcing data. Actual costs vary by ingredient complexity, payment terms, and regulatory jurisdiction. Not financial advice.
© 2026 SourcifyChina. Confidential. For Professional Use Only.
How to Verify Real Manufacturers
Professional B2B Sourcing Report 2026
Prepared for: Global Procurement Managers
Subject: Due Diligence Framework for Selecting a Capsule Contract Manufacturer in China
Date: April 5, 2026
Prepared by: SourcifyChina – Senior Sourcing Consultants
Executive Summary
Selecting a reliable capsule contract manufacturer (CM) is a pivotal decision for pharmaceutical, nutraceutical, and wellness brands. With increasing supply chain complexity and regulatory scrutiny, procurement managers must implement a rigorous verification process to mitigate risks related to product quality, compliance, and operational continuity.
This report outlines a step-by-step due diligence framework to authenticate manufacturers, distinguish between trading companies and actual factories, and identify critical red flags. The guidance is tailored for global procurement professionals sourcing from China, the world’s largest supplier of ODM/OEM capsule manufacturing services.
1. Critical Steps to Verify a Capsule Contract Manufacturer
| Step | Action | Purpose | Verification Method |
|---|---|---|---|
| 1.1 | Request Business License & GMP Certification | Confirm legal registration and compliance with pharmaceutical manufacturing standards. | Request scanned copies and verify via Chinese government portals (e.g., National Medical Products Administration – NMPA). Cross-check GMP certification scope includes hard/soft gelatin or vegetarian capsules. |
| 1.2 | Conduct On-Site Audit (or 3rd Party Audit) | Validate operational capacity, hygiene, equipment, and SOPs. | Engage a third-party inspection firm (e.g., SGS, TÜV, or SourcifyChina Audit Team) for GMP, ISO 22716, or cGMP audits. |
| 1.3 | Review Production Capacity & Equipment List | Assess scalability and technology alignment (e.g., automatic filling, encapsulation lines). | Request equipment list, line speed data, and batch production records. Confirm minimum order quantities (MOQ) match your demand. |
| 1.4 | Evaluate R&D and Formulation Support | Determine if the CM can assist in product development, stability testing, and regulatory dossiers. | Request case studies, formulation logs, and client references for similar projects. |
| 1.5 | Verify Regulatory Compliance | Ensure adherence to target market regulations (e.g., FDA 21 CFR, EU GDP, Health Canada). | Request evidence of FDA registration, DMF filings, or EU GMP certifications. Confirm export history to your region. |
| 1.6 | Check Raw Material Sourcing & Traceability | Ensure quality control of excipients and active ingredients. | Request CoA (Certificates of Analysis), vendor lists, and material traceability systems. |
| 1.7 | Perform Batch Sample Testing | Validate product quality, dissolution rate, and contamination levels. | Request pre-production samples tested at an independent lab (e.g., Eurofins, Intertek). |
| 1.8 | Review Client References & Case Studies | Assess reliability and client satisfaction. | Contact 2–3 past or current clients in your sector. Ask about delivery accuracy, communication, and issue resolution. |
2. How to Distinguish Between a Trading Company and a Factory
A common risk is engaging a trading intermediary posing as a manufacturer, which adds cost and reduces control. Use the following indicators:
| Indicator | Actual Factory | Trading Company |
|---|---|---|
| Business License | Lists “production” or “manufacturing” as core activity. | Lists “trading,” “import/export,” or “sales” only. |
| Facility Photos | Shows production lines, clean rooms, encapsulation machines, QC labs. | Generic office images or stock photos. |
| Equipment Ownership | Can provide serial numbers, maintenance logs, and machine specifications. | Unable to detail machinery or access real-time production status. |
| Pricing Structure | Quotes based on raw material + labor + overhead. Transparent cost breakdown. | Adds significant markup; vague on production costs. |
| Lead Times | Provides detailed production schedules, mold preparation, and filling timelines. | Offers generic timelines without process detail. |
| On-Site Access | Allows unannounced or scheduled factory visits with production walkthroughs. | Delays visits or arranges tours at third-party facilities. |
| R&D Capability | Has in-house formulation scientists, pilot batches, and stability testing. | Relies on partner labs or outsourced development. |
✅ Pro Tip: Use Baidu Maps or satellite imagery (Google Earth) to verify the factory’s physical footprint and production area size.
3. Red Flags to Avoid When Selecting a Capsule Manufacturer
| Red Flag | Risk Implication | Recommended Action |
|---|---|---|
| Unwillingness to Provide GMP or ISO Certification | High risk of non-compliance and product rejection. | Disqualify immediately. |
| No Physical Address or Refusal to Allow Factory Audit | Likely a trading company or shell entity. | Require third-party audit before proceeding. |
| Overly Low Pricing vs. Market Average | Indicates substandard materials, labor exploitation, or hidden costs. | Conduct full cost benchmark analysis. |
| Poor English Communication or Delayed Responses | Suggests weak project management and post-contract support. | Assign a sourcing agent or bilingual project manager. |
| No Experience with Your Target Market Regulations | Risk of failed customs clearance or regulatory non-approval. | Require documented export history to your region. |
| Requests Full Payment Upfront | High fraud risk. | Insist on milestone-based payment (e.g., 30% deposit, 40% pre-shipment, 30% after QA). |
| Generic or Stock Product Photos | Indicates lack of customization capability. | Request custom prototype and batch-specific photos. |
4. Best Practices for Mitigating Risk
- Use Escrow or LC Payments: For first-time orders, use Letters of Credit or secure payment platforms.
- Sign a Quality Agreement: Define responsibilities, CoA requirements, deviation handling, and recall procedures.
- Require Batch-Specific Documentation: Each shipment should include CoA, CoC (Certificate of Conformity), and packing list.
- Leverage a Local Sourcing Partner: Engage a reputable sourcing agent (e.g., SourcifyChina) for audits, QC, and logistics oversight.
Conclusion
The global demand for private-label capsules is rising, but so are supply chain risks. Procurement managers must adopt a structured, evidence-based approach to manufacturer verification. By confirming GMP compliance, conducting on-site audits, distinguishing real factories from traders, and watching for red flags, organizations can secure reliable, compliant, and scalable manufacturing partnerships.
SourcifyChina Recommendation: Prioritize transparency, regulatory alignment, and operational visibility over cost savings alone. The lowest price today may incur the highest cost tomorrow.
Prepared by:
Senior Sourcing Consultant
SourcifyChina – Strategic Sourcing & Supply Chain Assurance
www.sourcifychina.com | [email protected]
Get the Verified Supplier List
SourcifyChina Sourcing Intelligence Report 2026
Strategic Supplier Acquisition: Capsule Contract Manufacturing in the Global Health & Wellness Sector
Prepared for Global Procurement Leadership Teams | Q1 2026 Forecast
Executive Insight: The Time-Cost Imperative in Capsule Manufacturing Sourcing
Global procurement managers face unprecedented pressure to accelerate time-to-market while mitigating supply chain risks. In the $12.8B capsule manufacturing sector (Grand View Research, 2025), 73% of sourcing delays stem from unverified supplier claims – including misrepresented GMP compliance, capacity fraud, and hidden subcontracting. Traditional RFQ processes consume 147+ hours per qualified supplier (APICS 2025 Benchmark), directly impacting ROI and innovation cycles.
Why SourcifyChina’s Verified Pro List Eliminates Sourcing Friction
Our AI-verified Pro List for capsule contract manufacturers delivers immediate operational leverage through:
| Traditional Sourcing Process | SourcifyChina Pro List Advantage | Time Saved/Impact |
|---|---|---|
| Manual vetting of 20+ suppliers via Alibaba/Trade Shows | Pre-qualified 5 suppliers meeting your exact specs (GMP, ISO 13485, capacity, material certs) | 120+ hours per project |
| 3-6 month validation cycles (audits, samples, compliance checks) | Real-time access to triple-verified facilities (on-site SourcifyChina audit + 3rd-party lab reports + legal compliance) | Accelerated launch by 8-11 weeks |
| Hidden costs from failed audits (avg. $18,500/supplier per Gartner) | Zero-risk onboarding: All suppliers cleared for FDA/EMA/CFDA regulations | $50K+ saved per engagement |
| Unpredictable lead times due to subcontracting | Direct factory access (zero brokers); capacity locked via SourcifyChina’s SLA-backed agreements | On-time delivery ↑ 37% (2025 Client Data) |
Key Differentiator: Our Pro List is not a directory. Each supplier undergoes SourcifyChina’s 36-Point Verification Protocol, including:
– ✅ Live production capacity verification (IoT sensor data integration)
– ✅ Material traceability audits (from raw gelatin to finished capsule)
– ✅ Ethical compliance scoring (SMETA 4-Pillar certified)
– ✅ Real-time capacity dashboards (updated hourly via factory API)
Your Strategic Call to Action: Secure 2026 Supply Chain Resilience Now
Procurement leaders who act before Q2 2026 will capture 22% lower unit costs (SourcifyChina 2026 Cost Index) amid rising resin prices and regulatory tightening. The Pro List isn’t just a tool – it’s your force multiplier for strategic sourcing.
✨ “SourcifyChina’s Pro List cut our capsule supplier onboarding from 5 months to 17 days. We redirected 73% of vetting hours to product innovation.”
– Director of Global Sourcing, Top-5 Nutraceutical Brand (2025 Client Case Study)
Immediate Next Steps:
-
Claim Your Priority Access Slot
Our Pro List for capsule manufacturers has < 15 slots available for Q2 2026 engagements (demand has surged 200% YoY). -
Contact Us for a Zero-Cost, Zero-Commitment Assessment
Within 48 hours, receive: - A tailored shortlist of 3 pre-vetted capsule CMs matching your volume, regulation, and timeline
- Risk scorecard with compliance gaps identified
- Comparative FOB pricing analysis (2026 forward curves included)
Act Before May 31, 2026 to Lock Q2 Capacity & Secure 2026 Pricing Guarantees
📩 Email: [email protected]
📱 WhatsApp: +86 159 5127 6160
(Mention “2026 CAPSULE PRO LIST” for expedited processing)
Why wait? Every day spent on unverified suppliers erodes your Q3 margins. SourcifyChina delivers verified supply chain velocity – so you ship faster, with zero compliance surprises.
SourcifyChina: Where Verified Supply Meets Strategic Sourcing | ISO 9001:2015 Certified | 12,000+ Factories Vouched
© 2026 SourcifyChina. All data sourced from proprietary verification systems and third-party auditors. Not for redistribution.
🧮 Landed Cost Calculator
Estimate your total import cost from China.